Angina Pectoris, Stable
4
0
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Reducer System
Research Leaders
20 sponsors active, led by The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
25%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome
Effects of Ivabradine on Residual Myocardial Ischemia After PCI
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
Research Network
Common Treatments
- Reducer System1
- Standard Care1
- Buqitongluo Granule Placebo1
- Buqitongluo Granule1
- Heart Type Fatty Acid Binding Protein Testing1
Active Sponsors
- The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine1
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine1
- The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine1
- Shockwave Medical, Inc.1
- Chengdu University of Traditional Chinese Medicine1
Top Investigators
Department of Cardiovascular disease, Sapienza, University of Rome, Italy
Dongzhimen Hospital
Maastricht University
ZNA Middelheim Hospital
Related Conditions
- Acute Coronary Syndrome1
- Stroke Ischemic1
- Angina Pectoris Unstable1
- Coronary Artery Disease1
- Diabetic Peripheral Neuropathy1